Marinus Pharmaceuticals | search
Click here to view Marinus Pharmaceuticals news from 60+ newspapers.
Bookmark or Share- Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals Provides Update ...Marinus has decided to complete enrollment in the RAISE trial at approximately 100 patients with topline results expected in the summer of 2024. Those results will be used to determine whether to continue development of IV ganaxolone. Marinus remains blinded to the RAISE trial data.
- Pipeline - Marinus PharmaceuticalsMarinus Pharmaceuticals. About. About Us; Management Teams. Leadership; Board of Directors; Scientific Advisory Board; Support & Sponsorship; Medicine; Science & Pipeline. Our Science; Pipeline; Medical Affairs. Marinus Posters; Managed Access Programs; Investigator Initiated Studies; Focus Areas. Status Epilepticus (SE) BARDA Agreement ...
- Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals Announces FDA ...Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older1. ZTALMY significantly reduced major motor seizure frequency in CDD patients in the pivotal Marigold trial.
- Home - Marinus PharmaceuticalsMarinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders.
- Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals Announces U.S ...RADNOR, Pa.-- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the U.S. commercial launch of ZTALMY ® (ganaxolone) oral suspension, CV for the treatment of seizures associated with CDKL5 deficiency ...
More
